Barinthus Biotherapeutics (NASDAQ:BRNS) Issues Earnings Results

Barinthus Biotherapeutics (NASDAQ:BRNS) posted its quarterly earnings data on Wednesday. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01), Zacks reports.

Barinthus Biotherapeutics Stock Up 3.0 %

NASDAQ:BRNS traded up $0.03 on Thursday, hitting $1.02. The stock had a trading volume of 2,862 shares, compared to its average volume of 33,769. The stock has a market cap of $41.03 million, a price-to-earnings ratio of -0.68 and a beta of -0.80. The business’s 50-day simple moving average is $1.02 and its two-hundred day simple moving average is $1.12. Barinthus Biotherapeutics has a 52-week low of $0.80 and a 52-week high of $4.16.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reduced their price target on Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Monday, January 13th.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.